Innofend

Innofend is a biotech spin-off from Tampere University developing next-generation vaccines against pandemic viruses. Our lead product is a proprietary enterovirus platform using virus-like particles (VLPs). Our technology can safely and efficiently generate protective immune responses, even against viruses that can’t be targeted using traditional methods. We’re combining innovative science with scalability to close critical gaps in vaccine development.

  • Category: Biotech
  • Customer segment: B2B, B2G
  • Development stage: MVP / Preclinical
  • Funding stage: Pre-seed
  • Founding year: 2025
  • Team members: 2